Vertex Pharmaceuticals Incorporated (VRTX) Stock Valuation — DCF Analysis
Biotechnology · NASDAQ
Current Price
$444.93
Intrinsic Value
$569.15
+21.8% margin of safety
COMPETITIVE MOAT
↑Cystic Fibrosis Monopoly
Vertex holds a dominant global position in cystic fibrosis treatments. This entrenched market leadership creates significant barriers to entry for competitors.
↑Strong R&D Pipeline
The company's successful development of povetacicept for IgA Nephropathy demonstrates its ability to innovate. This pipeline expansion diversifies revenue streams and strengthens its competitive edge.
↑High Switching Costs
Patients on Vertex's CF therapies have limited alternatives. The effectiveness and established treatment protocols make switching to a new therapy difficult and risky.
INVESTMENT RISKS
↓Regulatory Hurdles
The FDA's decision on povetacicept in November 2026 is a key event. Any delay or rejection could impact future growth prospects.
↓Competition in New Areas
While strong in CF, Vertex faces established players in other therapeutic areas it enters. New drug development always carries inherent competitive risks.
↓Pricing Pressures
As a leader in high-cost treatments, Vertex may face increasing scrutiny and pressure on drug pricing from payers and governments.
Base case
VRTX base case valuation
A base case discounted cash flow model for VRTX estimates an intrinsic value of about $569.15 per share, against a current price of $444.93. The model assumes 12.5% annual free cash flow growth, a 10.0% discount rate, and a 30x exit multiple.
Intrinsic Value
$569.15
Margin of safety
+21.8%
Expected annual return
+5.0%
Base case assumptions: 12.5% annual growth, 10.0% discount rate, 30x exit multiple, 5 year projection. Data as of 2026-06-12.
This base case uses default assumptions and is not financial advice. The intrinsic value changes significantly when the growth rate or discount rate changes. Open the calculator to set your own assumptions and see the full sensitivity range.
Customize the VRTX valuation
Adjust the growth rate, discount rate, and exit multiple to see how the intrinsic value and margin of safety for Vertex Pharmaceuticals Incorporated respond.
Open DCF Calculator for VRTXCompany Overview
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.
Financial Metrics — VRTX Stock Valuation Data
Revenue/Share (TTM)
$48.23
FCF/Share (TTM)
$14.60
ROIC (TTM)
17.7%
ROE (TTM)
23.9%
P/FCF
30.4x
EV/EBITDA
20.5x
FCF Yield
3.29%
Debt/Equity
0.10x
Based on trailing twelve-month data, VRTX shows a free cash flow per share of $14.60 and a ROIC of 17.7%, key inputs for stock valuation using the DCF method. The P/FCF ratio of 30.4x and FCF yield of 3.29% are important context metrics when evaluating VRTX's stock valuation relative to peers.
Frequently Asked Questions
What is the intrinsic value of VRTX?
Vertex Pharmaceuticals Incorporated currently generates $14.60 in free cash flow per share. At the current price of $444.93, a DCF model would discount these cash flows at an appropriate WACC and apply a terminal growth rate to arrive at an intrinsic value. The result depends heavily on your growth and discount rate assumptions — a 1% change in WACC typically shifts the fair value estimate by 10-15%. In MiniValuator the model uses a single discount rate that you can edit directly, 10% by default, rather than a computed WACC.
Is VRTX undervalued?
VRTX trades at a P/FCF ratio of 30.4x with a free cash flow yield of 3.29%. This P/FCF is in a moderate range. However, whether VRTX is truly undervalued requires comparing the DCF intrinsic value to the current market price and evaluating whether the margin of safety is sufficient for your risk tolerance.
How do I value VRTX stock using DCF?
To perform a DCF valuation on Vertex Pharmaceuticals Incorporated: (1) Start with the trailing free cash flow per share ($14.60) as the base, (2) project future FCF growth over 5-10 years based on Biotechnology industry trends and company fundamentals, (3) apply a discount rate (WACC) reflecting VRTX's risk profile — with a debt-to-equity of 0.10x, capital structure is an important factor, and (4) add a terminal value for cash flows beyond the projection period.
What is DCF valuation and how does it apply to VRTX?
DCF (Discounted Cash Flow) estimates what a company is worth today based on its future cash generation. For Vertex Pharmaceuticals Incorporated, this means projecting how much free cash flow the company will produce over the next 5-10 years, shaped by Biotechnology trends, then discounting those amounts to today's dollars. VRTX's ROIC of 17.7% indicates strong capital efficiency, which supports higher growth assumptions in the DCF model.
How does WACC affect VRTX stock valuation?
WACC (Weighted Average Cost of Capital) is the discount rate in a DCF model — it reflects the minimum return investors require. For VRTX, with a debt-to-equity ratio of 0.10x, the capital structure directly influences WACC. A 1% increase in WACC typically reduces the intrinsic value by 10-15%. At an EV/EBITDA of 20.5x, the market's implied discount rate can be reverse-engineered for comparison. In MiniValuator you set this discount rate yourself as a single editable number, 10% by default, instead of computing a formal WACC.
Learn More
- See VRTX PE Valuation → — Earnings-based stock valuation using PE ratio analysis
- DCF Methodology — Step-by-step guide to discounted cash flow analysis
- PE Methodology — Guide to PE ratio stock valuation
- WACC — Understanding the discount rate used in DCF
- Margin of Safety — How to evaluate downside protection
- Intrinsic Value — How to evaluate stock fair value
- How to Calculate Intrinsic Value — Complete guide for investors
Related Valuations
All Healthcare valuationsDCF and P/E value VRTX with different methods and assumptions, so the two conclusions can differ. Compare the P/E fair value.
Price as of 2026-06-12. Financial data from Financial Modeling Prep (trailing twelve months) · Valuation methodology by Charlie Wang.
This is an estimate, not investment advice.